PMID- 26988130
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20220330
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 25
IP  - 6
DP  - 2016 Jun
TI  - Investigational therapies for Ewing sarcoma: a search without a clear finding.
PG  - 679-86
LID - 10.1517/13543784.2016.1168398 [doi]
AB  - INTRODUCTION: Ewing sarcoma family tumors (ESFT) are a group of aggressive 
      diseases, characterized histologically by small, round, blue cells and 
      genetically by translocation involving EWS and ETS partner genes. The current 
      treatment of localized Ewing sarcoma (ES) requires a multi-disciplinary approach, 
      including multidrug chemotherapy, administrated before and after local treatment, 
      surgery and radiation therapy. Unfortunately, the cure rate of metastatic or 
      refractory/recurrent disease is still very poor. AREAS COVERED: In this review, 
      the authors summarize the new types of therapy and strategies aimed to improve 
      the prognosis or cure ES. Herein, the authors discuss several preclinical and 
      phase I-II studies with new-targeted therapies. The most studied therapies are 
      insulin-like growth factor receptor (IGF1R) inhibitors but have limited efficacy. 
      Other strategies include Mammalian Target of Rapamycin (mTOR) Inhibition, poly 
      ADP ribose polymerase (PARP) inhibition, vascular endothelial growth factor 
      (VEGF) inhibition, tyrosine kinase inhibitors and telomerase inhibitors, all with 
      limited effectiveness. EXPERT OPINION: Future treatment strategies should combine 
      one or more targeted therapies with conventional chemotherapy. Some combined 
      modality treatments are under clinical study. However, treatment breakthroughs 
      are still needed to improve the relatively poor prognosis of recurrent/metastatic 
      ESFT.
FAU - Vornicova, Olga
AU  - Vornicova O
AD  - a Division of Oncology, Rambam Health Care Campus and Faculty of Medicine , 
      Technion-Israel Institute of Technology , Haifa , Israel.
FAU - Bar-Sela, Gil
AU  - Bar-Sela G
AD  - a Division of Oncology, Rambam Health Care Campus and Faculty of Medicine , 
      Technion-Israel Institute of Technology , Haifa , Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160407
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Bone Neoplasms/*drug therapy/pathology
MH  - Combined Modality Therapy
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
MH  - Sarcoma, Ewing/pathology/*therapy
MH  - Therapies, Investigational/*methods
OTO - NOTNLM
OT  - Ewing sarcoma family tumors
OT  - IGF1R
OT  - PARP
OT  - mTOR
OT  - review
OT  - target therapy
EDAT- 2016/03/19 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/03/19 06:00
PHST- 2016/03/19 06:00 [entrez]
PHST- 2016/03/19 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - 10.1517/13543784.2016.1168398 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2016 Jun;25(6):679-86. doi: 
      10.1517/13543784.2016.1168398. Epub 2016 Apr 7.